Source:http://linkedlifedata.com/resource/pubmed/id/11181146
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2001-2-22
|
| pubmed:abstractText |
The feasibility of providing postexposure prophylaxis (PEP) after sexual or injection drug use exposures to human immunodeficiency virus (HIV) was evaluated. PEP was provided within 72 h to individuals with exposures from partners known to have or to be at risk for HIV infection. PEP consisted of 4 weeks of antiretroviral medications and individually tailored risk-reduction and medication-adherence counseling. Among 401 participants seeking PEP, sexual exposures were most common (94%; n=375). Among sexual exposures, receptive (40%) and insertive (27%) anal intercourse were the most common sexual acts. The median time from exposure to treatment was 33 h. Ninety-seven percent of participants were treated exclusively with dual reverse-transcriptase inhibitors, and 78% completed the 4-week treatment. Six months after the exposure, no participant developed HIV antibodies, although a second PEP course for a subsequent exposure was provided to 12%. PEP, after nonoccupational HIV exposure, is feasible for persons at risk for HIV infection.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Didanosine,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/Nelfinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Reverse Transcriptase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0022-1899
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
183
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
707-14
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11181146-Adolescent,
pubmed-meshheading:11181146-Adult,
pubmed-meshheading:11181146-Aged,
pubmed-meshheading:11181146-Anti-HIV Agents,
pubmed-meshheading:11181146-Contact Tracing,
pubmed-meshheading:11181146-Counseling,
pubmed-meshheading:11181146-Didanosine,
pubmed-meshheading:11181146-Female,
pubmed-meshheading:11181146-HIV Infections,
pubmed-meshheading:11181146-Humans,
pubmed-meshheading:11181146-Lamivudine,
pubmed-meshheading:11181146-Male,
pubmed-meshheading:11181146-Middle Aged,
pubmed-meshheading:11181146-Nelfinavir,
pubmed-meshheading:11181146-Patient Compliance,
pubmed-meshheading:11181146-Reverse Transcriptase Inhibitors,
pubmed-meshheading:11181146-Risk Factors,
pubmed-meshheading:11181146-Risk-Taking,
pubmed-meshheading:11181146-Sexually Transmitted Diseases, Viral,
pubmed-meshheading:11181146-Substance Abuse, Intravenous,
pubmed-meshheading:11181146-Time Factors,
pubmed-meshheading:11181146-Zidovudine
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
|
| pubmed:affiliation |
Positive Health Program, Dept. of Medicine, University of California-San Francisco, at San Francisco General Hospital, 995 Potrero Ave., San Francisco, CA 94110, USA. jkahn@php.ucsf.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|